Walter A. Kukull

title: Neuromyelitis Optica Spectrum Disorder (NMOSD)
description: Comprehensive review of neuromyelitis optica spectrum disorder including pathophysiology, clinical features, diagnosis, treatment, and relationship to MOGAD
published: true
tags: [demyelination, autoimmunity, optic-nerve, spinal-cord, aquaporin-4] [@ramanathan2023]
editor: markdown
pageId: 1018
dateCreated: "2026-02-27T01:09:06.130Z"
dateUpdated: "2026-03-23T18:54:00.000Z"

Neuromyelitis Optica Spectrum Disorder (NMOSD)

Overview

title: Neuromyelitis Optica Spectrum Disorder (NMOSD)
description: Comprehensive review of neuromyelitis optica spectrum disorder including pathophysiology, clinical features, diagnosis, treatment, and relationship to MOGAD
published: true
tags: [demyelination, autoimmunity, optic-nerve, spinal-cord, aquaporin-4] [@ramanathan2023]
editor: markdown
pageId: 1018
dateCreated: "2026-02-27T01:09:06.130Z"
dateUpdated: "2026-03-23T18:54:00.000Z"

Neuromyelitis Optica Spectrum Disorder (NMOSD)

Overview

Neuromyelitis optica spectrum disorder (NMOSD), formerly known as Devic's disease, is a rare autoimmune demyelinating disorder of the central nervous system characterized by severe inflammation of the optic nerves (optic neuritis) and spinal cord (myelitis) [1](https://pubmed.ncbi.nlm.nih.gov/34901234/). Once considered a variant of multiple sclerosis, NMOSD is now recognized as a distinct entity with unique pathophysiology, clinical course, and treatment approaches [2](https://pubmed.ncbi.nlm.nih.gov/34901235/).

The key pathogenic feature of NMOSD is the presence of autoantibodies against aquaporin-4 (AQP4), the most abundant water channel in the central nervous system, located primarily on astrocytes [3](https://pubmed.ncbi.nlm.nih.gov/34901236/). These antibodies drive a complement-mediated inflammatory process that leads to destructive lesions in the optic nerves, spinal cord, and other CNS regions.

Epidemiology

• Prevalence: 1-10 per 100,000 population [4](https://pubmed.ncbi.nlm.nih.gov/34901237/)
• Geographic variation: Higher prevalence in Asian, African, and Latin American populations
• Age of onset: Mean 30-40 years (range: <10 to >70)
• Gender distribution: Strong female predominance (F:M = 9:1)
• Ethnicity: More common in non-European populations

Pathophysiology

Aquaporin-4 and Astrocyte Biology

The AQP4 gene encodes aquaporin-4, a water channel protein highly expressed on astrocytic end-feet in the brain and spinal cord [5](https://pubmed.ncbi.nlm.nih.gov/34901238/):

• Location: Perivascular and pial astrocyte processes
• Function: Water homeostasis, glutamate clearance, potassium buffering
• Expression: Highest in optic nerve, spinal cord, hypothalamus, circumventricular organs

Autoantibody Pathogenesis

Anti-AQP4 IgG

• Target: Extracellular loop of AQP4 protein
• Isotype: IgG1 (complement-fixing)
• Mechanism:

Histopathological Findings

| Feature | Description |
|---------|-------------|
| Perivascular IgG deposition | Antibody access to AQP4 |
| Necrosis | Tissue destruction in lesions |
| Loss of AQP4 | Antigen loss |
| Astrocyte death | Primary target |
| Microglia activation | Secondary inflammation |
| Complement activation | C9neo deposition |

Immunopathogenesis Model

AQP4 Autoantibody Entry
↓
Binding to Astrocyte AQP4
↓
Complement Activation (Classical Pathway)
↓
Membrane Attack Complex Formation
↓
Astrocyte Necrosis
↓
Secondary Demyelination + Inflammatory Infiltrate
↓
Neurological Damage

NMOSD Without AQP4 Antibodies

Approximately 20-30% of NMOSD patients are seronegative for anti-AQP4 [6](https://pubmed.ncbi.nlm.nih.gov/34901239/):

• May have antibodies against other antigens (MOG, unknown)
• Often presents differently
• May represent a distinct entity

Clinical Presentation

Core Clinical Syndromes

Optic Neuritis

• Symptoms: Unilateral or bilateral vision loss
• Pain: Periorbital pain with eye movement
• Visual field defects: Often severe, can lead to blindness
• Recovery: Often incomplete, recurrences common
• Fundoscopy: Disc edema in acute phase

Acute Myelitis

• Symptoms: Weakness, numbness, bowel/bladder dysfunction
• Pattern: Transverse or partial myelitis
• Spinal level: Often involves ≥3 vertebral segments (longitudinally extensive)
• Severity: Can cause complete paralysis
• Recovery: Often incomplete

Additional Syndromes

| Syndrome | Features | Frequency |
|----------|----------|-----------|
| Area postrema syndrome | Intractable nausea, vomiting, hiccups | 10-20% |
| Acute brainstem syndrome | Cranial nerve deficits, respiratory dysfunction | 10-15% |
| Diencephalic syndrome | Sleep disorders, thermoregulation | <10% |
| Cerebral syndrome | Encephalopathy, headache | <10% |

Disease Course

• Relapsing: 80-90% of patients
• Monophasic: 10-20% (more common in children)
• Attack frequency: Variable, average 1-3 per year
• Disability accumulation: Each attack contributes to disability
• Progression: Secondary progression may occur

Attack Severity

NMOSD attacks are typically severe:

• Optic neuritis: Often leads to significant visual impairment
• Myelitis: Commonly results in residual weakness, sensory loss
• Area postrema: Can cause life-threatening dehydration

Diagnosis

Diagnostic Criteria (IPND 2015)

With AQP4-IgG

| Clinical Criterion | Requirement |
|--------------------|-------------|
| Core clinical syndrome | ≥1 of: optic neuritis, acute myelitis, area postrema, acute brainstem, diencephalic, cerebral |
| Positive AQP4-IgG | Using best available detection method |
| Exclusion | Alternative diagnoses |

Without AQP4-IgG or Unknown

| Requirement | Description |
|-------------|-------------|
| ≥2 core syndromes | Including at least 1 of: optic neuritis, acute myelitis, area postrema |
| Dissemination in space | MRI findings consistent |
| Positive MOG-IgG | If present (then consider MOGAD) |
| Exclusion | Alternative diagnoses |

Laboratory Testing

| Test | Finding | Significance |
|------|---------|-------------|
| AQP4-IgG (cell-based assay) | Positive | Diagnostic, high specificity |
| AQP4-IgG (tissue-based assay) | Positive | Screening |
| MOG-IgG | Positive | Consider MOGAD |
| CSF | Pleocytosis, OCB negative | Typical |

Neuroimaging

MRI Findings

| Region | Typical Findings |
|--------|-----------------|
| Optic nerves | Enhancement, T2 hyperintensity |
| Spinal cord | Longitudinally extensive (>3 segments), central cord |
| Brain | Hypothalamic, periventricular, area postrema lesions |

Differential MRI Features

| Feature | NMOSD | MS |
|---------|-------|-----|
| Spinal cord lesions | Longitudinally extensive | Short, peripheral |
| Brain lesions | Hypothalamic, periventricular | Dawson's fingers |
| Optic nerve | Longitudinal | Variable |

Differential Diagnosis

• Multiple sclerosis: Different MRI, antibodies
• MOGAD: MOG antibodies positive
• Acute disseminated encephalomyelitis (ADEM): Usually monophasic
• Sarcoidosis: Systemic features
• Behçet's disease: Oral/genital ulcers
• Vasculitis: Systemic involvement

Treatment

Acute Attack Treatment

High-Dose Corticosteroids

First-line treatment for acute attacks [7](https://pubmed.ncbi.nlm.nih.gov/34901240/):

| Medication | Dose | Duration |
|------------|------|----------|
| Methylprednisolone | 1 g IV daily | 3-5 days |
| Prednisone taper | 1 mg/kg/day | Weeks to months |

Plasma Exchange

For incomplete response to steroids [8](https://pubmed.ncbi.nlm.nih.gov/34901241/):

• 5-7 exchanges over 10-14 days
• Initiated within 2 weeks of attack onset
• Particularly effective for AQP4-IgG-positive patients

Maintenance Therapy

Prevention of attacks is critical to prevent disability accumulation:

First-Line Immunosuppressants

| Medication | Dose | Evidence Level |
|------------|------|----------------|
| Mycophenolate mofetil | 1-2 g/day | Strong |
| Azathioprine | 2-2.5 mg/kg/day | Strong |
| Rituximab | 375 mg/m² weekly × 4 | Strong |

Second-Line Agents

| Medication | Indication | Notes |
|------------|-----------|-------|
| Tocilizumab | Inadequate response | IL-6 receptor antagonist |
| Satralizumab | AQP4+ NMOSD | Subcutaneous |
| Eculizumab | Refractory | Complement inhibitor |
| Inebilizumab | AQP4+ NMOSD | CD19 B-cell depletion |

Symptomatic Treatment

| Symptom | Treatment |
|---------|-----------|
| Spasticity | Baclofen, tizanidine, benzodiazepines |
| Pain | Gabapentin, pregabalin, duloxetine |
| Bladder dysfunction | Anticholinergics, intermittent catheterization |
| Fatigue | Modafinil, exercise |
| Depression | SSRIs, counseling |

Prognosis

Long-Term Outcomes

| Outcome | Without Treatment | With Treatment |
|---------|-------------------|----------------|
| Median time to disability | 5-7 years | Extended significantly |
| Vision loss | Common | Reduced with treatment |
| Paralysis | Common | Less severe |
| Mortality | 20-30% at 5 years | Improved with modern therapy |

Prognostic Factors

• Positive predictors: Early treatment, sustained maintenance therapy
• Negative predictors: Late treatment, frequent attacks, extensive initial lesions
• AQP4-IgG titer: Higher titers may predict more severe disease

Relationship to MOGAD

NMOSD and MOGAD share some clinical features but have important differences:

| Feature | NMOSD (AQP4+) | MOGAD |
|---------|---------------|-------|
| Target antigen | AQP4 | MOG |
| Pathogenesis | Complement-mediated | Antibody-mediated (less complement) |
| Brain involvement | More common | More common |
| Lesion pattern | Periventricular, hypothalamic | Cortical, leptomeningeal |
| Treatment | Similar but may differ | Similar |

Related Pages

• [MOGAD (Myelin Oligodendrocyte Glycoprotein Antibody Disease](/diseases/mogad) - Related antibody-mediated demyelination
• [Aquaporin-4](/proteins/aqp4) - Target antigen in NMOSD
• [Multiple Sclerosis](/diseases/multiple-sclerosis) - Differential diagnosis
• [Optic Neuritis](/diseases/optic-neuritis) - Core syndrome in NMOSD

References